Mid East/N African Survey on #SpA referrals. - 190 Rheum responded (68% consultants, 53% tertiary,95% urban) - 89% reported delay in axSpA presenting (most: Ortho, FP, internists) - 2/3 Dx challenges - > 60^ Pt non-adherence (side effects or Sx improvement) https://t.co/6jBdOqp2gM

Mayo study of 659 incident RA pts finds Multimorbidity predicted 29% (OR:1.29) higher odds of RA flare, & 34% lower (OR:0.66) odds of remission. RA Flares assoc w/ female, smoking, younger age shorter Dz duration, but not seropositivity. Remission assoc w/ male, not smoking, https://t.co/yEwkQ63zIh

Inefficiencies of ANA Testing The Journal of Rheumatology has published an analysis of antinuclear antibody (ANA) multiplex testing showing its nonspecific utility and poor rate of return in identifying ANA-associated autoimmune rheumatic disease (ARDs). https://t.co/hojdPPtCcI

2025 BSR Recommendations for ANCA-associated Vasculitis The BSR and BHPR have published a guideline for the management of adults with AAV; specifically three conditions: GPA, MPA, and EGPA. https://t.co/nYpbBK7Ahr https://t.co/XcfL4KRHlj

Novartis announced top line results of its ianalumab (VAY736;B cell inhibitor) in primary Sjögren’s dz. 2 RCTs, NEPTUNUS-1 and NEPTUNUS-2, met met primary endpoints w/ statistically significant improvements in disease activity in Sjögren’s patients. https://t.co/cIBhF3YJh3 https://t.co/YRTq6LEFhm

Rheums Speak - RA Treatment Survey RheumNow's August 2025 “Live Vote” surveys will examine Rheumatologist impressions, knowledge and practices over the last 20 years when treating rheumatoid arthritis. https://t.co/hJSQ5mMJ6b https://t.co/7sBXpzkVLg

Aging Quiets Lupus UCSF researchers have found that epigentic changes in interferon genes over time may lead to lupus being less active as they age. https://t.co/MLBFLXnXOQ https://t.co/9aacdZPoED

Full read review of DMARD effects on CV Risks. Strongest CV protective effects for MTX & TNF inhibitors. Potentially beneficial are sulfasalazine, hydroxychloroquine, & leflunomide. More info needed on IL-6, IL-17/23 inhibitors. Concerns over NSAIDs & JAKi https://t.co/0BW4StS15N

Large metanalysis of TNFi use in immune-mediated inflammatory diseases (45 studies, 150K pts) shows no increased risk of de novo heart failure (HF), and no significant risk of HF worsening w/ TNFis. https://t.co/9sRVsMZ1kv https://t.co/igCdcQMVK3

FDA Approves Vagal Nerve Stimulator for RA SetPoint Medical announced the FDA approved the SetPoint System, a neuroimmune modulation treatment for moderate-to-severe rheumatoid arthritis (RA), for patients not well-managed or cannot tolerate—existing RA therapies like https://t.co/MtVny1iBQ4

Smoking and the Global Burden of Rheumatoid Arthritis Detailed analysis of the Global Burden of Disease (GBD) 2021 database shows that tobacco and smoking is one of the most significant environmental risk factors for RA over the last 20 years. https://t.co/4IDf1ZTl7w https://t.co/oM0bNXIw28

RA leads to ILD: but ILD does not lead to RA New research sheds light on the link between rheumatoid arthritis (RA) and idiopathic pulmonary fibrosis (IPF). A team from Taizhou Hospital used advanced multi-omics methods to explore the causal relationship between these two https://t.co/QbY6GC0KBZ

Juvenile Idiopathic Arthritis - NEJM Review Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM). https://t.co/ykI9zAUXaF

DID YOU KNOW? >30% of Systemic Sclerosis pts present without Raynauds!. Data from 2 large US cohorts, of SSc dx with puffy fingers/hands or other symptoms. Such patients presented with more severe skin and musculoskeletal disease. https://t.co/NP3KeUL5iX https://t.co/XWiAIljujL